Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin
Aclarubicin (also called aclacinomycin A) is an antineoplastic from the anthracycline class that is used in China and Japan but not in Europe nor in the USA. Aclarubicin induces much less DNA damage than the classical anthracyclines doxorubicin, daunorubicin, epirubicin, idarubicin, and the anthrace...
Saved in:
| Main Authors: | Giulia Cerrato, Allan Sauvat, Mahmoud Abdellatif, Guido Kroemer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2515176 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospective Observational Study on the Risk Factors of Chemotherapy-Induced Myelosuppression and Its Management in a Tertiary Care Hospital
by: D. Keziah, et al.
Published: (2024-10-01) -
Mitochondrial DNA transfer between malignant cells and T lymphocytes shapes the cancer-immunity dialogue
by: Liwei Zhao, et al.
Published: (2025-12-01) -
Patritumab deruxtecan induces immunogenic cell death
by: Sabrina Forveille, et al.
Published: (2025-12-01) -
Datopotamab deruxtecan induces hallmarks of immunogenic cell death
by: Sabrina Forveille, et al.
Published: (2025-08-01) -
AI-based classification of anticancer drugs reveals nucleolar condensation as a predictor of immunogenicity
by: Giulia Cerrato, et al.
Published: (2024-12-01)